Page last updated: 2024-12-10
3,3'-diallyldiethylstilbestrol
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
3,3'-diallyldiethylstilbestrol: RN given refers to (E)-isomer; RN for cpd without isomeric designation not available 12/89 [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
ID Source | ID |
---|---|
PubMed CID | 3036605 |
CHEMBL ID | 230346 |
SCHEMBL ID | 10016276 |
MeSH ID | M0170940 |
Synonyms (16)
Synonym |
---|
3,3'-diallyldiethylstilbestrol |
4-[(1e)-1-ethyl-2-(4-hydroxy-3-prop-2-enylphenyl)but-1-enyl]-2-prop-2-enylphenol |
2-allyl-4-[(e)-2-(3-allyl-4-hydroxy-phenyl)-1-ethyl-but-1-enyl]phenol |
CHEMBL230346 |
w6u293x04b , |
unii-w6u293x04b |
4870-88-6 |
dades |
phenol, 4,4'-(1,2-diethyl-1,2-ethanediyl)bis(2-(2-propenyl)-, (e)- |
SCHEMBL10016276 |
4,4'-stilbenediol, 3,3'-diallyl-.alpha.,.alpha.'-diethyl-, (e)- |
phenol, 4,4'-((1e)-1,2-diethyl-1,2-ethenediyl)bis(2-(2-propenyl)- |
4,4'-((1e)-1,2-diethyl-1,2-ethenediyl)bis(2-(2-propen-1-yl)phenol) |
phenol, 4,4'-((1e)-1,2-diethyl-1,2-ethenediyl)bis(2-(2-propen-1-yl)- |
(e)-4,4'-(hex-3-ene-3,4-diyl)bis(2-allylphenol) |
Q27891430 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Bioassays (9)
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID292084 | Cytotoxicity against human PBM cells | 2007 | Bioorganic & medicinal chemistry letters, Aug-15, Volume: 17, Issue:16 | Synthesis, cytotoxicity, and antiviral activities of new neolignans related to honokiol and magnolol. |
AID292083 | Antiviral activity against HIV1 in human PBM cells | 2007 | Bioorganic & medicinal chemistry letters, Aug-15, Volume: 17, Issue:16 | Synthesis, cytotoxicity, and antiviral activities of new neolignans related to honokiol and magnolol. |
AID292081 | Antiproliferative activity against mouse SVR cells at 10 ug/mL after 72 hrs | 2007 | Bioorganic & medicinal chemistry letters, Aug-15, Volume: 17, Issue:16 | Synthesis, cytotoxicity, and antiviral activities of new neolignans related to honokiol and magnolol. |
AID292082 | Antiproliferative activity against mouse SVR cells at 15 ug/mL after 72 hrs | 2007 | Bioorganic & medicinal chemistry letters, Aug-15, Volume: 17, Issue:16 | Synthesis, cytotoxicity, and antiviral activities of new neolignans related to honokiol and magnolol. |
AID1552550 | Partition coefficient, log P of the compound | 2019 | Bioorganic & medicinal chemistry, 08-15, Volume: 27, Issue:16 | Anti-proliferative activity and structure-activity relationship of honokiol derivatives. |
AID292086 | Cytotoxicity against Vero cells | 2007 | Bioorganic & medicinal chemistry letters, Aug-15, Volume: 17, Issue:16 | Synthesis, cytotoxicity, and antiviral activities of new neolignans related to honokiol and magnolol. |
AID292087 | Inhibition of tumor growth in SVR cells bearing mouse up to 100 mg/kg, ip after 30 days | 2007 | Bioorganic & medicinal chemistry letters, Aug-15, Volume: 17, Issue:16 | Synthesis, cytotoxicity, and antiviral activities of new neolignans related to honokiol and magnolol. |
AID292085 | Cytotoxicity against human CEM cells | 2007 | Bioorganic & medicinal chemistry letters, Aug-15, Volume: 17, Issue:16 | Synthesis, cytotoxicity, and antiviral activities of new neolignans related to honokiol and magnolol. |
AID292088 | Toxicity against mouse up to 100 mg/kg, ip after 30 days | 2007 | Bioorganic & medicinal chemistry letters, Aug-15, Volume: 17, Issue:16 | Synthesis, cytotoxicity, and antiviral activities of new neolignans related to honokiol and magnolol. |
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Research
Studies (5)
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 1 (20.00) | 18.7374 |
1990's | 2 (40.00) | 18.2507 |
2000's | 1 (20.00) | 29.6817 |
2010's | 1 (20.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 12.64
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.64) All Compounds (24.57) |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 6 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |